Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Long-term outcomes of anti-CD19 CAR-T in R/R CLL

David L. Porter • 1 Sep 2020
SOHO 2020
Chronic Lymphocytic Leukemia Leukemia

David L. Porter, MD, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, explores the long-term outcomes from a Phase II, randomized dose optimization study of CAR-modified T-cells in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David L. Porter

4:47
CD19 CAR T-cells for adults
David L. Porter • 1 Sep 2020
4:23
Impact of COVID-19 on CAR T-cell therapies
David L. Porter • 1 Sep 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals